Tiziana Life Sciences announced that a preclinical study of its intranasal foralumab in combination with semaglutide (Ozempic / Wegovy) demonstrated synergistic effects in a mouse model of obesity, improving liver function and reducing inflammation more than semaglutide alone. The company says … [Read More...] about Tiziana says study of intranasal foralumab in addition to semaglutide demonstrated synergistic effects in mouse model of obesity

MannKind Corporation has announced that data from a recently completed Phase 1 study of MNKD-201 nintedanib DPI support continued development of the inhaler for the treatment of idiopathic pulmonary fibrosis (IPF). MannKind had announced plans for the Phase 1 SAD/MAD study earlier this year. The … [Read More...] about MannKind announces that results of Phase 1 trial of MNKD-201 nintedanib DPI support continued development

Kither Biotech has announced the initiation of a Phase 1 trial of its KIT2014, an inhaled peptide that the company is developing as a CFTR enhancer for use as an add-on with CFTR modulators for the treatment of cystic fibrosis. The SAD/MAD study is expected to enroll 72 healthy volunteers and will … [Read More...] about Kither Biotech announces initiation of Phase 1 trial of KIT2014 inhaled CFTR enhancer